CellOrigin Biotech Collaborated with Qilu Pharma to Develop Off-the-Shelf CAR-iMAC Cell Therapy for Cancer
Shots:
- The companies collaborated to develop "off-the-shelf" CAR-iMAC cell therapy for cancer immunotherapy
- The collaboration will combine both companies’ technologies and expertise along with the R&D capabilities, manufacturing, and marketing to develop CAR-iMAC clinical products for the treatment of solid tumors
- CellOrigin Biotech focuses to develop innovative technologies in cell therapy and builds a valuable products pipeline & also plans to work with other collaborators to explore and develop innovative anti-tumor drugs to address the unmet needs of cancer patients. Qilu has launched 200+ products with 30+ products "first to launch" in China and 3 products "D181 launch" in the US
Ref: PRNewswire | Image: CellOrigin Biotech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
